Should I buy Tilray Brands stock in 2025? (NZ Edition)

What is Tilray Brands?

How much is the Tilray Brands stock?

The price of Tilray Brands stock is rising this week. As of now, Tilray trades at $0.4646 USD with a 24-hour increase of +3.31%, though the weekly change shows a decline of -3.94%.

The company holds a market capitalisation of $471.99 million USD and an average 3-month trading volume of 27.61 million shares.

Tilray does not currently report a P/E ratio due to ongoing losses, offers no dividend yield, and has a stock beta of 2.02—indicating notable price volatility.

Investors in NZ should be mindful that while recent sessions are positive, the stock’s high beta signals potential for swift market swings.

Our full analysis on the Tilray Brands stock

Having carefully reviewed Tilray Brands’ latest financial results and its share price evolution over the past three years, our analysis synthesizes a range of data—from core financial metrics to technical chart signals, sector trends, and peer comparisons—refined by our proprietary algorithms. This comprehensive approach provides a holistic understanding of the company's trajectory within the diversified cannabis and alternative beverage landscape. So, why might Tilray Brands stock once again become a strategic entry point into the global cannabis and wellness sector in 2025?

Recent Performance and Market Context

Tilray Brands (NASDAQ: TLRY; TSX: TLRY) has experienced pronounced volatility, with its share price currently at $0.4646 USD—up 3.31% on the last trading day—fluctuating between $0.4100 and $2.1500 in the past year. While the stock is down significantly year-to-date (-65.07%) and over twelve months (-74.33%), this retracement has occurred in the context of sector-wide challenges for cannabis and wellness companies, particularly regarding regulation and capital availability.

However, several recent events have begun to shift sentiment:

• Solid intraday rebound and resilient support near multi-year lows: The recent bounce signals market participants are alert to oversold conditions and the potential for revaluation.
• Major strategic rationalisations and cost cuts deployed in 2025 (notably the "Project 420" cost savings and SKU reductions) are enhancing profitability and organisational resilience.
• Expansion of hemp-derived THC beverage distribution to 10 US states with more than 1,000 retail points demonstrates real access to fast-growing wellness categories.
• International momentum, with post-legalisation medical cannabis sales in Germany surging 79% in volume—evidence of leadership in newly opening markets.
• A powerful sector backdrop: The demographic overlap between alcohol and cannabis consumers is increasing, and legalisation discussions in the United States and Europe suggest regulatory tides may soon shift favourably. These set the stage for an upward rerating for well-positioned leaders.

Together, these structural and tactical positives reframe the current share price weakness as a potential setup for medium-term recovery.

Technical Analysis

A closer look at Tilray Brands’ technical structure indicates a stock approaching compelling technical junctures:

• RSI: The 14-day Relative Strength Index stands at approximately 41.78, just above oversold territory, indicating limited downside and scope for technical rebound, particularly as momentum stabilises.
• MACD: Momentum remains subdued, with the MACD below zero but with signs of flattening. This can often foreshadow bullish reversals, especially following long periods of sector stress.
• Moving Averages: TLRY currently trades below the major moving averages, reflecting recent pressure. However, historic patterns in high-beta, consumer-facing disruptors like Tilray have shown that such deep discounts can precede robust recovery phases as sentiment improves.
• Key supports: Firm technical support is established near the 52-week low at $0.4138. Bulls are watching this area as a risk-managed entry point given its resilience across multiple testing periods.
• First-target resistances: Overhead resistance appears around $0.50–$0.60, which also aligns with the converging moving average bands. A close above this zone may spark a momentum-driven rally, as prior volume accumulations could fuel a move toward $1.35—the current consensus analyst target.

The technical landscape, marked by significant support and early reversal cues, positions Tilray at an attractive inflection point for investors with a focus on “buy-the-dip” opportunities in undervalued growth stories.

Fundamental Analysis

Despite past share price disappointments, Tilray Brands’ fundamental profile has decisively strengthened:

• Resilient Revenues: Q3 FY2025 revenues reached $185.8 million, essentially stable on an FX-neutral basis ($193 million), even as the company prioritised SKU rationalisation and premiumisation over raw volume expansion.
• Margin Expansion: Gross margin advanced to 28%—a 200bps year-on-year improvement—reinforcing the company’s successful drive toward operational efficiency. This is particularly compelling as cannabis margins (41%) and beverage margins (36%) both improved, despite industry-wide pricing pressure.
• Strategic Diversification: Tilray is now a global leader in cannabis (Canada), the #1 player in infused beverages, chocolates, and oils, and boasts a top-5 US craft brewing position. Its European business is unmatched in medical cannabis infrastructure and regulatory readiness.
• Balance Sheet Strength: With $248.4 million in cash and short-term investments and net debt under 1x EBITDA (~$50 million), the company remains well-resourced even as it aggressively reduces debt obligations—$71 million eliminated in the last twelve months.
• Valuation Re-rating Potential: While current profitability is negative (TTM EPS: -$1.10; no P/E ratio), the market capitalisation of under $472 million stands at a steep discount to the sum-of-parts and revenue guidance for 2025 ($850–$900 million). The price-to-sales multiple is notably low for a company with category leadership and global reach, suggesting a rerating case as cash flow inflects.

Core strengths such as innovation, scale, and brand leadership position Tilray Brands to capture revenue stabilisation and margin upside as regulatory and consumption tailwinds gather momentum.

Volume and Liquidity

A defining feature of Tilray’s investment case is the exceptionally deep trading liquidity and high float:

• Reported average daily volume stands at 27.61 million shares, reflecting consistent engagement by global institutional and retail investors.
• The free float—at over 1.02 billion shares—ensures tight bid-ask spreads and supports dynamic price discovery, which can amplify upward moves when sentiment and sector flows inflect.

This robust liquidity profile affirms sustained market interest and positions Tilray for rapid valuation shifts as the narrative evolves, making it particularly suitable for active portfolio managers and individual investors seeking liquidity-driven rebound plays.

Catalysts and Positive Outlook

A series of imminent and longer-term catalysts underpin the positive outlook for TLRY:

• US Legalisation Upside: Even partial federal legalisation of medical cannabis in the United States could unlock an estimated $250M in incremental annual revenues for Tilray, given its ready-made production and distribution footprint.
• International Growth: Post-legalisation medical cannabis in Germany is already driving 79% volume growth, and Tilray’s distribution network covers Italy, Luxembourg, and Portugal—with additional “first-mover” potential as new markets open.
• Continued Product Innovation: New launches—from THC hemp-derived beverages to next-generation non-alcoholic drinks—tap into surging demand for alternative consumables and wellness products. The company also controls over 400 unique cannabis genetics, underpinning premium category leadership.
• Operational Optimization: Cost reductions of over 40% since 2024 and ongoing supply chain and SKU rationalisation reinforce the path towards profitability and capital efficiency—an increasingly valued trait in the global consumer sector.
• Favourable Macro Trends: Consumption patterns are evolving: 36% of Gen Z alcohol consumers now also consume cannabis (+14pts in 10 years), highlighting structural shifts that multifaceted groups like Tilray are best positioned to monetise.

These multi-layered catalysts, coupled with sector recovery prospects, set the stage for a positive re-evaluation, especially as operational execution translates into expanding margins and positive cash flow.

Investment Strategies

Given Tilray’s technical and fundamental backdrop, the stock presents compelling arguments for positioning across different investment horizons:

• Short-Term: Active investors can view current price levels—near historically robust support ($0.41)—as an opportune technical low. A tactical entry could benefit from short-covering rallies or positive headlines from regulatory reviews.
• Medium-Term: The next six to twelve months will be shaped by potential US legalisation, German growth, and margin delivery. Investors seeking multi-quarter appreciation can leverage the attractive price-to-sales ratio and observe for technical breakouts above $0.60.
• Long-Term: For those with a multi-year perspective and tolerance for volatility, Tilray’s diversified exposure across cannabis, beverages, wellness, and international platforms provides significant embedded optionality. As regulatory and societal acceptance broadens, the company’s leadership and scale could create a compounding effect on earnings and valuation.

Unlocking substantial upside may best be achieved by strategic entry at, or just above, current support zones—positioning ahead of anticipated sector catalysts and operational inflection points.

Is it the Right Time to Buy Tilray Brands?

To summarise, Tilray Brands combines the characteristics that often preface powerful rebounds in high-growth consumer and cannabis equities: undervalued multiples, sector-leading operations, strong liquidity, and a robust pipeline of near-term and structural catalysts. Disciplined cost control, geographic expansion, and category innovation support the case that the company is transitioning from defence to offence.

With technical support intact, operational indicators improving, and legalisation tailwinds gathering, the stock may well be entering a new bullish phase. While challenges persist, the current valuation seems to represent an excellent opportunity for investors who recognise the asymmetrical risk/reward profile ahead of what could be transformative regulatory and industry developments.

For those seeking exposure to the reinvigoration of the global cannabis and wellness sector, Tilray Brands warrants close consideration as a uniquely positioned player on the cusp of recovery and growth. The confluence of macro, operational, and technical factors reinforces the conviction that TLRY deserves renewed attention as a forward-looking portfolio addition in 2025—one that may reward patience and strategic entry as the next phase of revaluation unfolds.

How to buy Tilray Brands stock in NZ?

Buying Tilray Brands (TLRY) stock online as a New Zealand (NZ) investor is straightforward and secure when using a regulated broker. Investors can choose between two main methods: direct share (spot) purchase, where you own the underlying stock, or trading contracts for difference (CFDs), which allow you to speculate on price movements without owning shares. Both methods can be accessed safely online through reputable platforms—simply register, verify your identity, and fund your account in NZ dollars. To help you get started, we’ll compare brokers and their fees in detail further down the page.

Spot buying (Cash purchase)

When you purchase Tilray Brands shares directly, this means you become a shareholder—you own a real stake in the company. With most NZ-based or global brokers, you can buy TLRY shares listed on the NASDAQ in US dollars, with the broker converting your NZD deposit into USD. Typical fees for spot buying include a fixed commission per order, usually around NZ$5-10, plus a small currency conversion fee.

Example

Suppose the Tilray Brands share price is $0.4646 USD (approx. $0.75 NZD as of May 2025) and your total investment is NZ$1,000 (after accounting for a NZ$8 brokerage fee). You would be able to buy approximately 1,320 shares: - $1,000 - $8 = $992 available to invest - $992 / $0.75 = 1,322 shares (rounded to 1,320 after possible rounding and FX margin). Gain scenario: If the share price rises by 10% (to $0.83 NZD), your 1,320 shares are now worth about NZ$1,089. Result: That’s a gross gain of roughly NZ$100, or +10% on your initial investment (before potential FX or tax considerations).

Trading via CFD

CFD trading lets you speculate on Tilray Brands price movements using leverage, without actually owning the shares. With a CFD, you enter into a contract with the broker to settle the difference in price between when you open and close your position. Common fees include the spread (the small difference between buy/sell prices), and overnight financing charges for positions held open beyond a day.

Example

You decide to open a CFD position on TLRY with a NZ$1,000 margin and 5x leverage, giving you market exposure of NZ$5,000. If Tilray Brands shares rise by 8%, your position gains 8% × 5 = 40%. Result: That’s a profit of NZ$400 on your initial NZ$1,000 stake (excluding spreads and overnight fees).

Final advice

Before investing in Tilray Brands, it’s essential to compare brokers for their fees, currency conversion rates, platform features, and risk management tools. Each provider differs in costs and services, which can impact your returns. Whether you choose spot buying for real share ownership or CFDs for leveraged trading, your decision should reflect your personal goals and risk tolerance. For an overview of the best brokers for NZ investors, see our comparator further down the page to find the platform that suits you best.

Our 7 tips for buying Tilray Brands stock

The latest news about Tilray Brands

Tilray Brands reported a notable increase in gross margin to 28% and strong cash position in Q3 2025. Recent financial results highlighted a gross profit of $52 million, representing a 5% year-on-year rise and a 200 basis point improvement in gross margin, despite a slight drop in total revenue. This margin expansion reflects effective cost controls and operational efficiencies, with cash and negotiable securities totaling $248.4 million and net debt maintained below 1x EBITDA, indicating balance sheet strength that mitigates near-term liquidity risk for investors, including those in New Zealand seeking international diversification.

Tilray continues aggressive international expansion, with medical cannabis sales in Germany surging 79% post-legalisation. The company’s robust global strategy, particularly its leadership position in the German medical cannabis market—now the world’s largest importer—offers significant growth prospects. This international momentum, further evidenced by expansion in Italy, Luxembourg, and Portugal, benefits New Zealand investors exposed to global cannabis trends and illustrates Tilray’s ability to access new revenue pools outside North America.

The company finalized $71 million in debt reduction and maintained its cost-reduction trajectory under the Project 420 savings initiative. Tilray has now achieved $20.6 million of targeted savings, with a total planned impact of $33 million, alongside strategic SKU rationalization initiatives designed to optimize profitability. For institutional or retail investors watching global consumer sectors from New Zealand, these measures enhance the sustainability of Tilray’s business model at a time when cost discipline is prized amid sector volatility.

Tilray accelerated its U.S. footprint, expanding distribution of THC-derived beverages to 10 states and over 1,000 retail locations. This positions the company to capitalize on anticipated U.S. cannabis policy reform and addresses evolving consumer demand for alternative beverage formats. Although New Zealand’s regulatory framework currently restricts cannabis products, such U.S. expansion strengthens Tilray’s future optionality and revenue streams, which is relevant for NZ-based investors tracking global health and wellness product trends.

Analyst consensus maintains a 12-month price target of $1.35 USD, well above current levels, with positive sector tailwinds from Gen Z consumption trends. Despite ongoing share price weakness, the average analyst target implies significant upside potential. The company’s strong positions in both cannabis and beverage categories, coupled with a growing dual-use demographic (notably 36% of Gen Z drinking alcohol also consume cannabis, up 14 percentage points in the past decade), reinforce growth avenues that could drive improved sentiment and performance—an appealing consideration for NZ investors scanning undervalued global consumer stocks.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.